Controlled natural cycle IVF: a novel approach for a dominant follicle during an in-vitro maturation cycle.

The objective of this retrospective analysis is to evaluate whether patients developing a dominant follicle in an in-vitro maturation (IVM) programme can be included in a natural cycle IVF (nIVF) programme. In a university teaching hospital, a total of 38 patients with polycystic ovarian syndrome were treated by metformin before undergoing an IVM cycle. Controlled nIVF was performed on seven patients with a dominant follicle.

Could sperm aneuploidy rate determination be used as a predictive test before intracytoplasmic sperm injection?

Chromosome abnormalities in embryos are a major cause of implantation and development failures. Some couples with normal karyotypes have repeated implantation failures after intracytoplasmic sperm injection (ICSI). In order to value patients at risk for genetic ICSI failures and the validity of sperm aneuploidy analysis, we have studied cytogenetic abnormalities in sperm from ICSI patients.

Improvement of IVF results and optimisation of quality control by using intermittent activity.

For several years the present authors' team had not been satisfied with the pregnancy rate achieved by their unit, especially in comparison with the results achieved by other teams with a similar population. A quality programme was established, and it was decided to switch from non-stop to intermittent activity. It was envisaged that this programme would provide a more realistic view of the team's activity and could also, as a secondary effect, improve its results.

Reproductive genetic counselling in non-mosaic 47,XXY patients: implications for preimplantation or prenatal diagnosis: Case report and review.

With an incidence of approximately 1 in 500 male newborns, the 47,XXY genotype is one the most common sex chromosome anomalies. It is also the most frequent genetic cause of human infertility. Some non-mosaic 47,XXY patients have sperm production which allows infertility treatment to be offered by ICSI.